Abafungin
 | |
 | |
| Systematic (IUPAC) name | |
|---|---|
| N-[4-[2-(2,4-dimethylphenoxy)phenyl]-1,3-thiazol-2-yl]-1,4,5,6-tetrahydropyrimidin-2-amine | |
| Clinical data | |
| topical | |
| Identifiers | |
| 129639-79-8 | |
| None | |
| PubChem | CID 159326 |
| ChemSpider |
140124  |
| UNII |
11DI31LWXF |
| ChEBI | CHEBI:76005 |
| Chemical data | |
| Formula | C21H22N4OS |
| 378.491 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Abafungin (INN) is a broad-spectrum antifungal agent with a novel mechanism of action for the treatment of dermatomycoses.
Abasol is a topical cream formulation of abafungin by York Pharma.[1]
Mechanism of action
Unlike imidazole- and triazole-class antifungals, abafungin directly impairs the fungal cell membrane.[2]
In addition, abafungin inhibits the enzyme sterol 24-C-methyltransferase, modifying the composition of the fungal membrane.[3]
Abafungin has antibiotic activity against gram-positive bacteria as well as sporicidal activity.[4]
References
- ↑ York Pharma: Regulatory Update – Abasol
- ↑ Borelli C1, Schaller M, Niewerth M, Nocker K, Baasner B, Berg D, Tiemann R, Tietjen K, Fugmann B, Lang-Fugmann S, Korting HC. "Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi". Chemotherapy. 2008;54(4):245-59
- ↑ Borelli C1, Schaller M, Niewerth M, Nocker K, Baasner B, Berg D, Tiemann R, Tietjen K, Fugmann B, Lang-Fugmann S, Korting HC. "Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi". Chemotherapy. 2008;54(4):245-59
- ↑ Ginter-Hanselmayer, Gabriele (March 2009), Arbeitsunterlagen zur 42. wissenschaftlichen Fortbildungsveranstaltung für Apothekerinnen und Apotheker: Infektionskrankheiten, Österreichische Apothekerkammer, p. 103
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||